Physician
Integrated Pain Consultants, LLC
Integrated Pain Consultants, LLC was paid $2.90M by Medicaid between Jan 2018 and Dec 2024, across 59 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 61% of everything it billed.
33Billing provider infoINTEGRATED PAIN CONSULTANTS, LLC
SCOTTSDALE, AZ 85258
SCOTTSDALE, AZ 85258
33aNPI1538612965assigned 08/02/2016
33bProvider typeInterventional Pain Medicine Physician
28Total paid$2.90M
24GClaims81,149
24DCodes billed59
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Interventional Pain Medicine Physician providers in Arizona
Rank by total paid#1 of 9
Median peer was paid$502K
This provider vs. median5.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,071 | $333K | |
| 2019 | 11,494 | $328K | |
| 2020 | 12,217 | $498K | |
| 2021 | 15,390 | $565K | |
| 2022 | 18,684 | $717K | |
| 2023 | 5,490 | $205K | |
| 2024incomplete | 5,803 | $257K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 61% | 36,629 | 31,438 | $1.77M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 21% | 6,865 | 5,421 | $618K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 6.0% | 6,303 | 4,989 | $174K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.6% | 2,765 | 2,223 | $77K |
| 64483 | 1.6% | 263 | 223 | $47K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.1% | 480 | 388 | $33K |
| 64635 | <1% | 72 | 52 | $18K | |
| 64636 | <1% | 87 | 64 | $17K | |
| 01938 | <1% | 164 | 155 | $13K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 313 | 301 | $12K |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 285 | 37 | $11K |
| 01992 | <1% | 111 | 100 | $9K |
47 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,951 | $7K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 129 | $7K |
| 99152 | <1% | 455 | $7K | |
| 62321 | <1% | 31 | $6K | |
| 64633 | <1% | 19 | $6K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 233 | $6K |
| 64634 | <1% | 19 | $5K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 358 | $5K |
| 95943 | <1% | 66 | $5K | |
| 64484 | <1% | 67 | $4K | |
| 93923 | <1% | 68 | $4K | |
| 95923 | <1% | 66 | $4K | |
| 77002 | <1% | 48 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,163 | $3K |
| 20610 | <1% | 63 | $3K | |
| 96136 | <1% | 110 | $3K | |
| 01940 | <1% | 30 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 220 | $3K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 36 | $3K |
| 27096 | <1% | 14 | $2K | |
| 96103 | <1% | 285 | $2K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 17 | $2K |
| 96132 | <1% | 19 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 231 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,217 | $1K |
| 99490 | Ccm add 20min | <1% | 260 | $1K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 16 | $963.53 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 2,900 | $945.00 |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 15 | $814.18 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 38 | $703.17 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 19 | $661.02 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 25 | $529.67 |
| 96130 | <1% | 16 | $480.50 | |
| 96127 | <1% | 222 | $381.35 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 14 | $315.10 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 826 | $308.35 |
| 96138 | <1% | 19 | $241.46 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,883 | $195.16 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 86 | $133.52 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 324 | $99.79 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 343 | $22.36 |
| 82570 | 0% | 589 | $0.00 | |
| 99408 | 0% | 51 | $0.00 | |
| 83992 | 0% | 588 | $0.00 | |
| G0444 | Annual depression screening, 5 to 15 minutes | 0% | 19 | $0.00 |
| 83986 | 0% | 589 | $0.00 | |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | 0% | 55 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRYAN, MONICA (COO)